Literature DB >> 10381791

gamma-Hydroxybutyrate modulates synthesis and extracellular concentration of gamma-aminobutyric acid in discrete rat brain regions in vivo.

S Gobaille1, V Hechler, C Andriamampandry, V Kemmel, M Maitre.   

Abstract

gamma-Hydroxybutyrate possesses most of the properties of a neurotransmitter/neuromodulator that acts via specific pathways and receptors in brain. Beside its regulatory effects on dopaminergic transmission, gamma-hydroxybutyrate was thought for many years to interfere with gamma-aminobutyric acid (GABA)ergic processes in the brain. The present study demonstrates that in the rat frontal cortex in vivo, gamma-hydroxybutyrate or its agonist NCS-356 administered systemically at a high dose (500 mg/kg) increases GABA contents in dialysates via a mechanism blocked by the peripheral administration of the gamma-hydroxybutyrate antagonist NCS-382. Under the same conditions, the extracellular concentration of this amino acid was not modified in the hippocampus. However, when administered at a low dose (250 mg/kg), gamma-hydroxybutyrate decreases GABA content of the dialysates of the frontal cortex by an NCS-382-sensitive mechanism. Spontaneous [3H]GABA release was observed in the frontal cortex of rats at 160 min after i.p. [3H]-gamma-hydroxybutyrate administration. This result indicates that gamma-hydroxybutyrate in vivo could be the precursor of an extracellular GABA pool in the frontal cortex. After i.p. [3H]-gamma-hydroxybutyrate administration in the rat, the amino acid contents of several brain regions were quantified 160 min later, and the radioactivity in each region was measured. [3H]GABA, [3H]glutamate, and [3H]glycine were detected in most, but not all, of the brain regions studied. In particular, radioactive GABA was not detected in the hippocampus. The other amino acids were not labeled. These results show that gamma-hydroxybutyrate modulates the synthesis and the extracellular concentrations of GABA in specific regions of the rat brain. Identification of these GABA pools and determination of their functional role remain to be defined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381791

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid.

Authors:  Melanie A Felmlee; Samuel A Roiko; Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2010-03-09       Impact factor: 4.030

Review 2.  Neurosteroids, GABAA receptors, and ethanol dependence.

Authors:  Paolo Follesa; Francesca Biggio; Giuseppe Talani; Luca Murru; Mariangela Serra; Enrico Sanna; Giovanni Biggio
Journal:  Psychopharmacology (Berl)       Date:  2005-09-15       Impact factor: 4.530

3.  Alterations in neuronal transport but not blood-brain barrier transport are observed during gamma-hydroxybutyrate (GHB) sedative/hypnotic tolerance.

Authors:  Indranil Bhattacharya; Joseph J Raybon; Kathleen M K Boje
Journal:  Pharm Res       Date:  2006-08-10       Impact factor: 4.200

4.  Changes in GABA(A) receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal.

Authors:  Enrico Sanna; Maria Cristina Mostallino; Fabio Busonero; Giuseppe Talani; Stefania Tranquilli; Manuel Mameli; Saturnino Spiga; Paolo Follesa; Giovanni Biggio
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

5.  γ-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose.

Authors:  Bridget L Morse; Nisha Vijay; Marilyn E Morris
Journal:  Mol Pharmacol       Date:  2012-05-04       Impact factor: 4.436

Review 6.  γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Authors:  Melanie A Felmlee; Bridget L Morse; Marilyn E Morris
Journal:  AAPS J       Date:  2021-01-08       Impact factor: 4.009

7.  Characterization of the GHB Withdrawal Syndrome.

Authors:  Casper J H Wolf; Harmen Beurmanjer; Boukje A G Dijkstra; Alexander C Geerlings; Marcia Spoelder; Judith R Homberg; Arnt F A Schellekens
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.